Self-administration of factor and bypassing agents by persons with hemophilia in the home setting is recommended to facilitate earlier intervention after bleeding episodes. The objective of this review was to summarize recombinant activated coagulation factor VII (rFVIIa) safety and efficacy data from clinical trials and patient registries documenting use in the home treatment setting in people with congenital hemophilia with inhibitors (CHwI). A total of 16 studies and registries were identified for inclusion; 14 evaluated on-demand treatment of acute bleeding episodes (865 patients, 9024 bleeding episodes) and 2 evaluated use for secondary prophylaxis (108 patients, 42,861 prophylaxis days). In the on-demand studies, efficacy was consistently high (81%-96%), and thrombotic events were uncommon (n 5 3). In the secondary prophylaxis studies, rFVIIa was associated with a 45% to 59% reduction in bleeding episodes and no thrombotic events. These data support the clinical practice of administering rFVIIa in patients in the home treatment setting after initiation under a physician's care.
| I N T R O D U C T I O N
The management of congenital hemophilia in the home treatment setting is common and is advocated by current treatment guidelines, which, in light of the many potential advantages of home treatment relative to administration in treatment centers, recommend its use "where appropriate and possible." 1 This practice may facilitate earlier initiation of therapy after bleed onset, resulting in more rapid recovery from bleeding as well as reduced pain, dysfunction, emergency department visits, hospitalizations, long-term disability, and costs. [2] [3] [4] [5] [6] [7] Self-administration of replacement clotting factor products in the home setting may also facilitate earlier initiation of routine prophylaxis, which may reduce the risk of developing arthropathy and thereby improve long-term musculoskeletal outcomes. 8, 9 Moreover, patients may experience improvements in healthrelated quality of life because of greater freedoms accompanied by home treatment. 10 However, clotting factor replacement may be complicated by the development of inhibitors, where even high doses of clotting factor replacement products may be insufficient to prevent or control bleeding, requiring use of alternative "bypassing" agents for management.
Recombinant activated coagulation factor VII (rFVIIa, NovoSeven® RT, Novo Nordisk A/S, Bagsvaerd, Denmark) is a highly purified recombinant protein 11 that is approved for the treatment of bleeding episodes and the prevention of bleeding during surgery or invasive procedures in adults and children with congenital hemophilia with inhibitors (CHwI) as well as other congenital and acquired bleeding disorders.
12
The clinical use of rFVIIa in patients with CHwI is supported by a wealth of data spanning nearly 30 years. 13, 14 Current prescribing information stipulates that treatment should be initiated under the direction of a qualified health care professional and provides patient instructions for reconstitution and administration. 12 The rFVIIa formulation is well-suited for home use. It is roomtemperature stable, and thus does not require refrigeration when temperatures do not exceed 258C (778F). 12, 15 It retains its activity and stability for extended periods after reconstitution (for 6 hours at 258C
[778F] and for 24 hours at 58C [418F]). 16 Current US prescribing information recommends administration within 3 hours after reconstitution. 12 The rFVIIa injection is of low volume (1-8 mL, depending on the dose) and can be administered rapidly (over a period of 2-5 minutes). 12, 17, 18 
| Efficacy outcomes
Reported efficacy rates from the individual studies were extracted and efficacy definitions were recorded (Table 1 ).
| Safety outcomes
All reports of thromboembolic events (TEs) were recorded. Adverse events other than TEs were not included in the current review. Safety reporting requirements particularly in post-approval safety studies (PASS) are different for studies conducted in Japan, and specifically differences in reporting of all adverse events irrespective of relationship to product compared with PASS focus on adverse drug reactions possibly/probably related to products.
| Statistical methodology
All data were summarized; no statistical analyses were performed.
| R E S U LTS
A total of 16 studies evaluating rFVIIa home use were identified ( Figure   1 ). Fourteen of these studies assessed on-demand use (for the treatment of bleeding episodes) and 2 evaluated use for the prevention of bleeding in patients with established joint disease (secondary prophylaxis).
| On-demand treatment studies
A total of 793 patients were treated for 8758 bleeding episodes in the on-demand treatment studies (three phase 2 trials, two phase 3 trials, and nine phase 4 registries; Table 1 ). Both standard doses (90 mcg/kg) and high single doses (270 mcg/kg) were represented.
Dosing in observational studies was variable (at the discretion of the prescribing physician). No attempt to differentiate efficacy based on dosing regimen was made for the purpose of this review. Efficacy was consistently high across the 12 on-demand treatment studies for which efficacy outcomes were reported (691 patients; 7543 bleeding episodes). Using typical response criteria (which included the evaluation of bleeding, and in some studies, consideration of the need for additional hemostatic agents; see Table 1 for description of efficacy), rFVIIa provided effective hemostasis in 81% to 96% of the bleeding episodes.
Safety data were reported as part of the protocols as primary or secondary endpoints. For the current review, only the rates of TEs for all bleeding episodes in the 14 studies were extracted (perioperative management entered on bleeding episode forms was included in one registry). 19 Overall, TEs were rare. A total of 3 events were identified in 8758 episodes (0.034%), 2 in a single 10-year Japanese postmarketing vatreptacog alfa with rFVIIa. 21 In trials and registries where full safety information about the events including causality was available the overall thrombotic rate was 1/7040 bleeds (0.014%).
| Secondary prophylaxis studies
A total of 108 patients were treated with rFVIIa for a total of 42,861 treatment days in the 2 secondary prophylaxis studies (one phase 2 and one phase 4; Table 2 ). Dosing in the phase 2 prospective study (22 patients, 1885 prophylaxis days) was 90 mcg/kg or 270 mcg/kg daily. 22 Dosing in the phase 4 retrospective study (86 patients, 40 976 treatment days) varied and often changed over time. 23 Efficacy was evaluated as the frequency of bleeds during the prophylaxis period compared with the frequency of bleeds during a pre-prophylaxis period, and in both studies prophylaxis vs.
pre-prophylaxis was associated with reductions in bleeding frequency. In the phase 2 study, efficacy was evaluated as the number of bleeds per month during the 3-month prophylaxis period compared with the 3-month pre-prophylaxis period. Bleeding frequency in this study was reduced by 45% with the 90 mcg/kg dose (n 5 11) and 59% with the 270 mcg/kg dose (n 5 11; both P < .0001 vs. the pre-prophylaxis period). 22 In the phase 4 study where the period of prophylaxis depended on retrospective review of available medical records (range, 22 to 3651 days), bleeding frequency was reduced by 46% (95% CI, 254.0 to 238.2) for the total bleeding population (n 5 74; defined as patients with at least 1 bleed during the preprophylaxis period [12/86 patients were excluded from the analysis of change in bleed rate because they had no bleeds during the pre-
prophylaxis period]) and 52% (95% CI, 260.7 to 243.3) for the frequent bleeding population subset (n 5 36; defined as patients having at least 1 bleed per month during the pre-prophylaxis period). 23 There were no TEs reported in either of these studies. 
| DISCUSSION
The current review provides a summary of evidence regarding the efficacy and safety of rFVIIa in the home treatment setting. The rate of efficacy for the on-demand treatment of acute bleeding episodes across 12 studies and registries comprising 7543 bleeding episodes was high (84%-96%) and TEs were uncommon (n 5 3). Administration for secondary prophylaxis in 2 studies/registries (43 000 prophylaxis days), was associated with a 45%-59% reduction in bleeding episodes and no TEs.
The high rate of efficacy described herein is consistent with the range of efficacy reported in registration trials (71%-93%), 12, [24] [25] [26] [27] which comprised both patients treated at home and patients who received rFVIIa at hemophilia treatment centers. These findings suggest that patients who opt to self-administer rFVIIa at home or at their location may experience efficacy similar to what they would expect if rFVIIa were administered at a hemophilia treatment center in early clinical studies. Furthermore, treatment at home may facilitate more timely administration, 2,3 and thus more rapid recovery.
The low rate of TEs is also consistent with previous observations.
The current US prescribing information indicates that 0.2% of bleeding episodes in patients with CHwI in clinical trials were complicated by TEs. 12 Rates of TEs reported in previously published cumulative 32 These improvements would be expected to reduce costs relative to administration at treatment centers; however, such cost comparisons remain to be performed. Finally, the identification of any demographic or clinical characteristics associated with beneficial outcomes could aid the identification of patients most likely to benefit from home treatment.
In conclusion, this review of data from Novo Nordisk clinical trials and patient registries supports the safety and efficacy of rFVIIa when self-administered or administered by a trained caregiver in the home treatment setting. Extensive registry data confirm the findings of clinical trials and support that rFVIIa can be used under the direction of qualified health care professionals by patients and caregivers trained to infuse at home or the patient's location rapidly after the onset of a bleed to maximize the chances for a rapid and successful resolution of the episode, or to routinely infuse to prevent bleeding when so directed by a health care professional.
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